Trethera

Coming – November 9

Targeting Disease Without Compromising Immunity

Date and Time

November 9

–

12:00 PM ET / 9:00 AM PT

Details will be shared with confirmed attendees

About this Event

Exploring the Next Generation of Precision Treatments for Autoimmune Disease and Cancer

For decades, treating autoimmune diseases has presented a fundamental challenge: How do we stop the immune system from attacking healthy tissue without compromising its ability to protect us?

Today, advances in cellular biology and precision medicine are creating new possibilities.

Join this special Force For Knowledge Fireside Chat featuring Lawrence Steinman, MD, Professor of Neurology and Neurological Sciences at Stanford University, whose pioneering research helped lead to the development of Tysabri, an important treatment for multiple sclerosis, and Ken Schultz, MD, Chairman & CEO of Trethera, a clinical-stage biotechnology company developing a novel approach to treating autoimmune diseases and cancer.

At the center of the discussion is Trethera’s first-in-class drug candidate, TRE-515, designed to selectively inhibit an enzyme involved in the proliferation of disease-causing cells. Early research suggests the potential to suppress abnormal immune activity while preserving healthy immune function, an approach that could have important implications for diseases ranging from multiple sclerosis and optic neuritis to certain cancers.

Our conversation will explore the evolution of autoimmune treatments, the scientific discoveries driving the next generation of precision therapies, Trethera’s clinical development progress, and what these advances could mean for patients and the future of medicine.

Register today for this insightful discussion at the intersection of groundbreaking science, medical innovation, and the future of healthcare.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.